WebDisclosure WebDisclosure
Basculer en Français
9478 Companies
185488 Keywords
117867 Articles
99347 Press releases
Headlines Articles Press releases NANOBIOTIX Remove
  1. Home
  2. Companies
  3. NANOBIOTIX
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • PRESS RELEASE

    published on 05/14/2024 at 22:15, 1 year 6 months ago

    NANOBIOTIX annonce l'acceptation par l'Agence américaine du médicament, la FDA, d'un protocole pour une nouvelle étude randomisée de Phase 2 évaluant NBTXR3 pour les patients atteints d'un cancer du poumon de stade trois

    Nanobiotix annonce l'acceptation par la FDA d'un protocole pour une nouvelle étude de phase 2 sur NBTXR3 pour le cancer du poumon de stade III
    FDA Étude De Phase 2 NANOBIOTIX Cancer Du Poumon NBTXR3
    Logo of NANOBIOTIX
  • PRESS RELEASE

    published on 05/14/2024 at 22:15, 1 year 6 months ago

    NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

    Nanobiotix announces US FDA protocol acceptance for new randomized Phase 2 study on NBTXR3 for stage three lung cancer patients
    Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer FDA Protocol
    Logo of NANOBIOTIX
Previous page
1 ... 15 16
Accesswire
  • Published on 12/05/2025 at 16:00, 12 minutes ago

    SMX Didn't Change Its Story; The World Finally Connected the Dots

  • Published on 12/05/2025 at 15:45, 27 minutes ago

    Critical Elements announce la clôture d'un placement privé de 7,0 $ million ca par voie de prise ferme

  • Published on 12/05/2025 at 15:45, 27 minutes ago

    Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement

  • Published on 12/05/2025 at 15:35, 37 minutes ago

    XCF Global Moves to Double SAF Production with New Rise Reno Expansion

  • Published on 12/05/2025 at 15:25, 47 minutes ago

    Usha Resources Provides Corporate Updates

View all ACCESSWIRE
EQS Group
  • Published on 12/05/2025 at 16:00, 12 minutes ago

    EQS-Adhoc: TIN INN Holding AG implements financing strategy

  • Published on 12/05/2025 at 16:00, 12 minutes ago

    EQS-Adhoc: Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025

  • Published on 12/05/2025 at 16:00, 12 minutes ago

    Amundi Physical Metals plc: Communiqué de Mise à Disposition du Rapport Financier Semestriel au 30 septembre 2025

  • Published on 12/05/2025 at 16:00, 12 minutes ago

    Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025

  • Published on 12/05/2025 at 15:47, 25 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: NCC Group plc

View all EQS
Les Echos
  • Published on 12/05/2025 at 15:10, 1 hour 2 minutes ago

    Mersen: Number of shares and voting rights as of November 30, 2025

  • Published on 12/05/2025 at 15:10, 1 hour 2 minutes ago

    Mersen : nombre d'actions et de droits de vote au 30 novembre 2025

  • Published on 12/05/2025 at 13:58, 2 hours 14 minutes ago

    RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

  • Published on 12/05/2025 at 08:45, 7 hours 27 minutes ago

    Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie

  • Published on 12/05/2025 at 08:45, 7 hours 27 minutes ago

    Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2025 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy